Oritavancin
规格
171099-57-3CAS 号
(1S,2R,18R,19R,22S,25R,28R,40S)-2-[(2R,4S,5R,6S)-4-amino-5-hydroxy-4,6-dimethyloxan-2-yl]oxy-22-(2-amino-2-oxoethyl)-5,15-dichloro-48-[(2S,3R,4S,5S,6R)-3-[(2S,4S,5R,6S)-4-[[4-(4-chlorophenyl)phenyl]methylamino]-5-hydroxy-4,6-dimethyloxan-2-yl]oxy-4,5-dihyIUPAC 名称
C86H97Cl3N10O26化学式
1793.1 g/mol分子量
Oritavancin; 171099-57-3; LY333328; Chlorobiphenyl-chloroeremomycin; LY-333328; oritavancina; oritavancine; PUG62FRZ2E; CHEBI:82699; DTXSID20897570; (4''R)-22-O-(3-Amino-2,3,6-trideoxy-3-C-methyl-alpha-L-arabinohexopyranosyl)-N3''-(p-(p-chlorophenyl)benzyl)vancomycin; oritavancinum; oritavacin diphosphate; RefChem:57173; J01XA05; DTXCID701326917; Oritavancin [INN]; LY 333328; UNII-PUG62FRZ2E; CHEMBL1688530; Orita-vancin; C12034; ORITAVANCIN [MI]; ORITAVANCIN [VANDF]; ORITAVANCIN [MART.]; ORITAVANCIN [WHO-DD]; Oritavancin(LY-333328); Oritavancin; LY-333328; orb1692501; SCHEMBL9947049; SCHEMBL29416865; GTPL10877; VHFGEBVPHAGQPI-LXKZPTCJSA-N; BDBM513037; GLXC-10720; EX-A2372; HY-B1831; AKOS032944863; AA16180; DB04911; NCGC00485478-01; NCGC00485478-02; DA-66365; T37881; Q7102878; (4''R)-22-O-(3-AMINO-2,3,6-TRIDEOXY-3-C-METHYL-.ALPHA.-L-ARABINO-HEXOPYRANOSYL)-N(SUP 3)''-(P-(P-CHLOROPHENYL)BENZYL)VANCOMYCIN; (4''R)-22-O-(3-amino-2,3,6-trideoxy-3-C-methyl-alpha-L-arabino-hexopyranosyl)-N(3'')-((4'-chloro(1,1'-biphenyl)-4-yl)methyl)vancomycin; (4'R)-22-O-(3-Amino-2,3,6-trideoxy-3-C-methyl-alpha-L-arabino-hexopyranosyl)-N(sup 3)' -(p-(p-chlorophenyl)benzyl)vancomycin; (4R)-22-O-(3-Amino-2,3,6-trideoxy-3-C-methyl-a-L-arabinohexopyranosyl)-N3-(p-(p-chlorophenyl)benzyl)vancomycin; VANCOMYCIN, 22-O-(3-AMINO-2,3,6-TRIDEOXY-3-C-METHYL-.ALPHA.-L-ARABINO-HEXOPYRANOSYL)-N3''-((4'-CHLORO(1,1'-BIPHENYL)-4-YL)METHYL)-, (4''R)-同义词
